Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy as First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC): A Randomized, Controlled, Open-Label, Multicenter Phase III.

NCT07267806 is registered in ClinicalTrials.gov with Linhui Peng as lead sponsor.

NCT NCT07267806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07267806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy as First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC): A Randomized, Controlled, Open-Label, Multicenter Phase III.
Lead sponsor
Linhui Peng
Phase
Phase 3
Overall status
Recruiting
Start date
October 31, 2025
Completion date
October 31, 2032
Enrollment
326 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, hepato cellular carcinoma (hcc)